Clearside Biomedi (CLSD)

$0.93 +0.00 (0.53%)
Market Cap 70.53M
Revenue (ttm) 8.23M
Net Income (ttm) -32.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -394.78%
Debt to Equity Ratio 0.00
Volume 160,100
Avg Vol 270,184
Day's Range N/A - N/A
Shares Out 75.84M
Stochastic %K 24%
Beta 2.20
Analysts Strong Sell
Price Target $6.00

Latest News on CLSD

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Dec 19, 2024, 7:05 AM EST - 4 weeks ago

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Nov 25, 2024, 7:05 AM EST - 7 weeks ago

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:37 PM EST - 2 months ago

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Nov 7, 2024, 9:05 AM EST - 2 months ago

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 2 months ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Nov 4, 2024, 7:05 AM EST - 2 months ago

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Oct 31, 2024, 7:05 AM EDT - 2 months ago

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Oct 22, 2024, 7:05 AM EDT - 3 months ago

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Oct 9, 2024, 6:30 AM EDT - 3 months ago

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Aug 27, 2024, 7:05 AM EDT - 5 months ago

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 7:05 AM EDT - 5 months ago

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Aug 1, 2024, 7:05 AM EDT - 6 months ago

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Jul 24, 2024, 11:23 PM EDT - 6 months ago

Clearside Biomedical, Inc. (CLSD) Suprachoroidal Space Drug Delivery (Transcript)

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Jul 22, 2024, 12:00 PM EDT - 6 months ago

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Jul 11, 2024, 7:05 AM EDT - 6 months ago

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Jun 27, 2024, 7:05 AM EDT - 7 months ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

Why Is Clearside Biomedical Stock Gaining Today?

Jun 25, 2024, 12:54 PM EDT - 7 months ago

Why Is Clearside Biomedical Stock Gaining Today?

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Jun 12, 2024, 7:05 AM EDT - 7 months ago

Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

May 21, 2024, 7:05 AM EDT - 8 months ago

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

May 9, 2024, 9:14 PM EDT - 9 months ago

Clearside Biomedical, Inc. (CLSD) Q1 2024 Earnings Call Transcript

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:05 PM EDT - 9 months ago

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

May 8, 2024, 4:15 PM EDT - 9 months ago

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Apr 30, 2024, 7:05 AM EDT - 9 months ago

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Apr 16, 2024, 7:05 AM EDT - 9 months ago

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Mar 18, 2024, 7:05 AM EDT - 10 months ago

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 12:47 AM EDT - 11 months ago

Clearside Biomedical, Inc. (CLSD) Q4 2023 Earnings Call Transcript

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 4:05 PM EDT - 11 months ago

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Feb 29, 2024, 7:05 AM EST - 11 months ago

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Feb 7, 2024, 8:00 AM EST - 1 year ago

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Dec 14, 2023, 7:05 AM EST - 1 year ago

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:18 PM EST - 1 year ago

Clearside Biomedical, Inc. (CLSD) Q3 2023 Earnings Call Transcript

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 4:05 PM EST - 1 year ago

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 7:05 AM EST - 1 year ago

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Nov 7, 2023, 4:20 PM EST - 1 year ago

Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Nov 2, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Nov 1, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

Oct 31, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Oct 16, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

Oct 4, 2023, 9:00 AM EDT - 1 year ago

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

Oct 3, 2023, 4:35 PM EDT - 1 year ago

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Sep 19, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 4:05 PM EDT - 1 year ago

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

Aug 2, 2023, 4:30 PM EDT - 1 year ago

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

Aug 1, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

Jul 31, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

Jul 20, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical's Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Jul 17, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

Jul 11, 2023, 4:05 PM EDT - 1 year ago

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Jul 10, 2023, 7:05 AM EDT - 1 year ago

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema